Historical record - last NADAC effective date: 7/1/2016
Product Information
VELCADE 3.5 MG VIAL is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $1508.2109 per EA under NDC 63020004901. Its NADAC has been published 139 times since Nov 19, 2014.
FDA first approved this application on May 13, 2003. Its Orange Book therapeutic-equivalence code is AP.
The High Outlier badge above means this manufacturer's average price in the bortezomib market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
3.5 mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
63020004901
Classification
Brand
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
7/1/2016
Active Ingredients
BORTEZOMIBApproval Type
New Drug (NDA)
FDA Application
NDA021602FDA Approved
5/13/2003
TE Code
AP
On Market Since
5/13/2003
Pharmacological Classes
Price Statistics
The NADAC for VELCADE 3.5 MG VIAL has been published 139 times since Nov 19, 2014, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $1508.2109 per EA |
|---|---|
| All-time high | $1516.6740 (Jul 6, 2016) |
| All-time low | $1491.2640 (Nov 19, 2014) |
| Median price | $1508.2109 |
| Average price | $1510.0965 |
| Largest weekly change | +1.1% (Jan 14, 2015) |
| Weeks tracked | 139 |
| Tracking since | Nov 19, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+1.1%
Last surveyed Jul 12, 2017 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 97% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of VELCADE 3.5 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for VELCADE 3.5 MG VIAL, manufactured by Takeda Pharmaceuticals America, Inc., is $1508.2109 per EA (NDC 63020004901), effective Jul 12, 2017.
How has the price of VELCADE 3.5 MG VIAL changed over time?
Over the history we have for it, the NADAC for VELCADE 3.5 MG VIAL has held within roughly two percent of its current level. It has been tracked across 139 weekly CMS publications since Nov 19, 2014.
What are the highest and lowest recorded NADAC prices for VELCADE 3.5 MG VIAL?
Since Nov 19, 2014, the NADAC for VELCADE 3.5 MG VIAL has ranged from a low of $1491.2640 (Nov 19, 2014) to a high of $1516.6740 (Jul 6, 2016), with a median of $1508.2109 per EA.
Are there cheaper alternatives to VELCADE 3.5 MG VIAL?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BORTEZOMIB 3.5 MG VIAL, is $43.3460 per EA — about 97% below VELCADE 3.5 MG VIAL.
Who manufactures VELCADE 3.5 MG VIAL?
VELCADE 3.5 MG VIAL (NDC 63020004901) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.